Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer

Gastric Cancer

Volumn 17, Issue 1, 2014, Pages 97-106

  Hashimoto, Kousuke ^a   Aoyagi, Keishiro ^a   Isobe, Taro ^a   Kouhuji, Kikuo ^a   Shirouzu, Kazuo ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CD133; Gastric cancer; HIF 1 ; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOPLASM; DISEASE SPECIFIC SURVIVAL; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL RATE;

ANTIGENS, CD; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; FEMALE; GLYCOPROTEINS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PEPTIDES; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84891630302     PISSN: 14363291     EISSN: 14363305     Source Type: Journal    
DOI: 10.1007/s10120-013-0255-9     Document Type: Article

References (29)

1. Al-Hajj M, Clarke MF. Self-renewal and solid tumor stem cells. Oncogene. 2004;23:7274-82.
2. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature (Lond). 2004;432:396-401.
3. Eramo A, Lotti F, Sette G, Pilozzi E, Biffoni M, Di Virgilio A, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ. 2008;15:504-14.
4. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542-56.
5. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature (Lond). 2007;445:106-10.
6. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C. Identification and expansion of human colon cancer-initiating cells. Nature (Lond). 2007;445:111-5.
7. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 2007;1:313-23.
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946-51.
9. Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One. 2008;3:e2637.
10. Zhao P, Lu Y, Jiang X, Li X. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Cancer Sci. 2011;102:1107-11.
11. Hagiwara S, Kudo M, Ueshima K, Chung H, Yamaguchi M, Takita M, et al. The cancer stem cell marker CD133 is a predictor of the effectiveness of S1 + pegylated interferon α-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol. 2011;46:212-21.
12. Ong CW, Kim LG, Kong HH, Low LY, Lacopetta B, Soong R, et al. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod Pathol. 2010;23:450-7.
13. Hayashi T, Ding Q, Kuwahata T, Maeda K, Miyazaki Y, Matsubara S, et al. Interferon-alpha modulates the chemosensitivity of CD133-expressing pancreatic cancer cells to gemcitabine. Cancer Sci. 2012;103:889-96.
14. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, McKay RD, et al. Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1α. Oncogene. 2009;28:3949-59.
15. Sun C, Song H, Zhang H, Hou C, Zhai T, Huang L, et al. CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1α (HIF-1α). J Cancer Res Clin Oncol. 2012;138:1619-24.
16. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, et al. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. J Gastroenterol. 2010;45:896-902.
17. Matumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, Fujita Y, et al. mTOR signal and hypoxia-inducible factor-1α regulate CD133 expression in cancer cells. Cancer Res. 2009;69:7160-4.
18. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma. 3rd English edition. Gastric Cancer. 2011;14:101-12.
19. Isobe T, Aoyagi K, Koufuji K, Shirouzu K, Kawahara A, Taira T, et al. Clinicopathological significance of hypoxia-inducible factor-1alpha (HIF-1α) expression in gastric cancer. Int J Clin Oncol. 2012 (Epub ahead of print).
20. Horst D, Kriegl L, Engel J, Kirchner T, Jung A. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer. 2008;99:1285-9.
21. Maeda S, Shinchi H, Kurahara H, Mataki Y, Maemura K, Sato M, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer. Br J Cancer. 2008;98:1389-97.
22. Cheifec G, Capella C, Solcia E, Jao W, Gould V, et al. Amphicrine cells, dysplasias, and neoplasias. Cancer (Phila). 1985;56:2683-90.
23. Ishigami S, Ueno S, Arigami T, Uchikado Y, Setoyama T, Arima H, et al. Prognostic impact of CD133 expression in gastric carcinoma. Anticancer Res. 2010;30:2453-7.
24. Zhao P, Li Y, Lu Y. Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer. 2010;10:218.
25. Sasaki A, Kamiyama T, Yokoo H, Nakanishi K, Kubota K, Haga H, et al. Cytoplasmic expression of CD133 is an important risk factor for overall survival in hepatocellular carcinoma. Oncol Rep. 2010;24:537-46.
26. Takahashi S, Kamiyama T, Tomaru U, Ishizu A, Shida T, Osaka M, et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep. 2010;24:1201-12.
27. Jao SW, Chen SF, Lin YS, Chang YC, Lee TY, Wu CC, et al. Cytoplasmic CD133 expression is a reliable prognostic indicator of tumor regression after neoadjuvant concurrent chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol. 2012;19:3432-40.
28. Fukamachi H, Shimada S, Ito K, Ito Y, Yuasa Y. CD133 is a marker of gland-forming cells in gastric tumors and ox17 is involved in its regulation. Cancer Sci. 2011;102:1313-21.
29. Yang J, Yan H, Hui L, Hui NL, Lei Z, Wei H, et al. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer. Gastric Cancer. 2012;15:440-50.